Tenosynovial giant cell tumor (TGCT) is a mesenchymal tumor arising from the synovium of tendon sheath and joints, characterized by translocation t(1;2)(p13;q37). Clinical behaviors of TGCT range from favorable to locally aggressive and further research is required to lead the identification of novel therapeutic avenues for TGCT. Patient-derived cell lines are an indispensable tool for interrogating molecular mechanisms underlying the progression of disease. However, only one TGCT cell line is currently available from cell banks, and a paucity of adequate patient-derived cells hinders basic and translational research. This study aimed to establish a novel cell line of TGCT. To this end, a novel cell line, NCC-TGCT1-C1 was established from the primary tumor tissue of a 40-year-old female patient with TGCT. The cells exhibited translocation t(1;2)(p13;q37), generating COL6A3-CSF1 fusion gene. The cells were maintained as a monolayer culture through more than 30 passages over 12 months. The cells exhibited continuous growth and the ability for spheroid formation and invasion. When used in a high-throughput assay to evaluate the anti-proliferative effects of 164 anticancer drugs, the cells responded strongly to a kinase inhibitor such as gefitinib, and mitoxantrone. Our results indicate that the novel TGCT cell line, designated NCC-TGCT1-C1, was successfully established and could be used to study TGCT development and the effects of anticancer agents.

腱鞘巨细胞瘤（TGCT）是一种由腱鞘和关节滑膜引起的间质瘤，特征是易位t（1; 2）（p13; q37）。TGCT的临床行为范围从有利到局部侵略性不等，需要进一步研究来确定TGCT的新治疗途径。患者来源的细胞系是询问疾病进展基础分子机制的必不可少的工具。但是，目前只能从细胞库中获得一种TGCT细胞系，而且缺乏足够的患者来源的细胞阻碍了基础和翻译研究。这项研究旨在建立一种新型的TGCT细胞系。为此，从一名40岁TGCT女性患者的原发肿瘤组织中建立了一种新型细胞系NCC-TGCT1-C1。细胞表现出易位t（1;COL6A3-CSF1融合基因。在12个月中，经过30多次传代，将细胞保持为单层培养。细胞表现出连续的生长以及球体形成和侵袭的能力。当用于高通量分析以评估164种抗癌药物的抗增殖作用时，细胞对激酶抑制剂（如吉非替尼和米托蒽醌）产生强烈反应。我们的结果表明，成功建立了新型TGCT细胞系NCC-TGCT1-C1，可用于研究TGCT的发展和抗癌药的作用。